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Clinical genomics1. Introduction
Initial optimism over the sequencing of the human genome has
given way to more sober discussion of challenges posed by the com-
plexity of genomic information (Arnedos et al., 2014), the inadequacy
of many clinical studies (Holmes et al., 2009), the growing complexity
of bioinformatics (Fernald et al., 2011), the economics of personalized
medicine (Davis et al., 2009), and other factors (Chan and Ginsburg,
2011). The development of high-throughput sequencing techniques,
or next generation sequencing (NGS) (and now third- and fourth-gen-
eration sequencing) (Kulkarni and Pfeifer, 2015), could lay the founda-
tion for clinical integration of genomic data. However, NGS worsens all
the existing challenges for identifying relevant genomic discoveries,
studying beneﬁts and harms, and getting beneﬁcial discoveries from
the laboratory to the clinic for rapid patient access.ogy Policy, World Trade Center
21202, United States.
essner), shubha.c@duke.edu
. This is an open access article underAs a result, policymakers are increasingly focusing on ways to facili-
tate the development and application of genomic medicine. Most nota-
bly, President Obama's Precision Medicine Initiative focuses on
expanding cancer clinical trials and creating a voluntary database of in-
formation on a million-person cohort for a “big data” approach to
sorting out themeaning of human genetic variation (FACT SHEET). Sim-
ilarly, the 21st Century Cures initiative of the U.S. House Energy and
Commerce Committee focuses on the acceleration of innovative cures,
including the development of precision medicine (21st Century Cures).
Policy challenges must be addressed for such initiatives to succeed.
Legal commentators have speculated about what the policy challenges
will be, particularly as they relate to regulatory oversight of NGS, cover-
age and reimbursement of clinical NGS tests, and intellectual property
and data sharing (Kaufman et al., 2014; Javitt and Carner, 2014;
Deverka and Dreyfus, 2014; Cook-Deegan and Chankrasekharan,
2014; Evans, 2014). To effectively respond to these challenges,
policymakers need to tackle the most important and tractable issues
ﬁrst, taking account of the perspectives of multiple stakeholders.
To assess the relative importance and tractability of issues arising in
the clinical integration of DNA sequence data, we carried out a four-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Round 1 individual policy challenge assessment scores for importance.
Challenge description Scorea
Diagnostic companies are able to maintain proprietary databases on the
substantial variety of clinically meaningful mutations found in patients.
Refusal to share this type of information could impede the development
of clinical useful NGS tests.
77
The traditional framework many payers use for assessing diagnostic tests
for coverage cannot keep pace with the rate of NGS-based genomic
discovery.
73
Different payers have different evidentiary standards for assessing clinical
utility, leading to inconsistent policies on coverage and reimbursement
for NGS-based testing.
68
Some payers refuse to cover NGS because the speciﬁc information needed
for patient management is unclear when NGS-based testing is ordered.
67
Some payers refuse to cover NGS because the technology itself is
considered experimental, investigational, or unproven.
67
The traditional framework many payers use for assessing diagnostic tests
for coverage does not account for the future utility of heritable risk
prediction or associated prevention strategies.
59
The traditional framework many payers use for assessing diagnostic tests
for coverage cannot accommodate the discovery and use of rare variants
in precision medicine.
56
The submission of a claim to a payer for conﬁrmatory testing of incidental
ﬁndings is typically not covered by payers, since in this case, there is
either no diagnosis of the diagnosis does not appear clinically relevant to
the test being done.
55
Currently payers do not reimburse separately for the sequencing and
interpretative components of NGS testing.
55
cDNA and the short DNA sequences used as primers and probes in genetic
testing are still potentially protected, leaving open an avenue for
companies like Myriad to challenge would-be competitors offering
genetic testing and potentially hindering NGS companies from
developing clinically optimal diagnostic testing products and services.
55
The performance characteristics for analytic validity speciﬁed by CLIA do
not readily apply to NGS platforms due to the complexity of the
technology/bioinformatics needed for analysis and interpretation.
54
A company's ability to offer interpretive services may be limited by State
laws limiting the practice of medicine (including the clinical
interpretation of laboratory results for patients) to licensed
professionals.
50
An ongoing legal debate exists over whether genomic interpretation
should be deemed to be the practice of medicine.
50
It is unclear who, if anyone, would pay for periodic re-analyses of stored 47
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experts to identify and rank the most important policy challenges, and
to deliberate about solutions for the top four challenges. This paper de-
scribes the results of the ﬁrst two rounds of the Delphi process, which
were designed to identify the most important and most tractable bar-
riers to clinical adoption of NGS testing.
2. Materials and methods
We conducted a modiﬁed policy Delphi, an iterative survey tech-
nique conducted in roundswith a select groupof experts to assess a spe-
ciﬁc policy question (Linstone and Turoff, 1975; Turoff, 1970; Adler and
Ziglio, 1996). The Delphimethod as originally conceived in the 1950s by
RAND was designed as a homogeneous panel of experts responding to
questionnaires and developing consensus opinions asynchronously
and anonymously (Linstone and Turoff, 1975). Users of the technique
subsequently modiﬁed the approach for a wider range of applications.
The policy Delphi approach uses a heterogeneous group of experts to
explore differences of opinion and produce a range of policy options
(Turoff, 1970; Adler and Ziglio, 1996). We used a “modiﬁed” Delphi ap-
proach, which includes a round of well-facilitated direct interaction
among Delphi panelists (Fitch et al., 2001).
This project was designed to answer two questions in succession –
one question for each two rounds. The ﬁrst two rounds of this study
asked: what is the group's collective judgement regarding themost im-
portant and tractable barriers to the clinical adoption of NGS? The sec-
ond two rounds asked: for the most important barriers identiﬁed,
what are proposed policy solutions? The answer to the ﬁrst question
is meaningful and worth detailed consideration in itself. In addition,
since the method design is modular, reporting on the ﬁrst module has
no effect on the conduct of the second module. Hence we have elected
to report this result now, while we continue to explore the answer to
the second question.
For the purposes of this study, we deﬁned ‘expert’ as a person with
professional expertise or signiﬁcant lay knowledge in the ﬁeld of genet-
ics, government, health policy, patient advocacy, or law. A history of
NGS-related publications, presentations, or service on task forces or
public committees was evidence of expertise. Experts were contacted
by email and offered an honorarium of $100 per round of completed
Delphi. Out of 93 invitations sent, 48 experts agreed to participate. The
ﬁnal composition of the participants is displayed in Table 1.
An initial list of challenges was developed based on preliminary re-
search (Holmes et al., 2009; Curnutte et al., 2014), including work pub-
lished by the project team in a series of papers (Kaufman et al., 2014;
Javitt and Carner, 2014; Deverka and Dreyfus, 2014; Cook-Deegan and
Chankrasekharan, 2014; Evans, 2014), and on project team member
subject matter expertise. This initial series of 19 potential policy chal-
lenges potentially hampering clinical NGS was assessed by the Delphi
panel in the ﬁrst round. The challenges spanned three topic areas:Table 1
Expert stakeholder composition of Delphi panel.
Primary profession N (%)
Genomic researcher 8 (17%)
Clinician or health care provider 3 (6%)
Payer 3 (6%)
Research funder 2 (4%)
Regulator or policy maker 3 (6%)
Lawyer or legal scholar 5 (10%)
Informatician 1 (2%)
Health economist 2 (4%)
Product developer 4 (8%)
Patient advocate 4 (8%)
Social scientist 2 (4%)
Industry funder 2 (4%)
Other 9 (19%)
TOTAL 48 (100%)intellectual property (3 challenges), regulation (6 challenges), and cov-
erage and reimbursement (10 challenges).
At the end of Round 1, the challenges deemedmost important by the
participants were analyzed using a weighted scoring system. Points
were assigned as: “strongly agree” = 2, “agree” = 1, “disagree” =−1,
1, “strongly disagree” = −2. The scale was normalized to run from
−100 to 100:−100 thus represented strong disagreement of all panel-
ists; 100 represented strong agreement of all panelists. A cutoff score of
60 was used to select challenges that would advance to Round 2 for re-
assessment (i.e., challenges generally agreed to be important moved to
the next round for further assessment).NGS data given that under current policies, a re-analysis not prompted
by a speciﬁc clinical question or diagnosis would likely be challenged.
If sequencing and interpretive services bifurcate into separate services
offered by different companies, it is unclear which federal or state
agency would have the authority to regulate freestanding interpretive
services.
44
Without FDA review of LDTs for safety and efﬁcacy for clinical use, patients
may be put at risk.
43
While recent Supreme Court rulings have reduced some uncertainty about
what kind of diagnostic molecules and methods can be patented, there
remains lingering uncertainty about patent eligibility that may dampen
incentives to develop genomic diagnostics products and services.
40
In the absence of clinical diagnostic claims, the FDA's authority to regulate
NGS platforms as laboratory-developed tests (LDTs) is unclear.
39
Reimbursement policy may drive whether NGS raw data output will
become part of a patient's clinical record or whether only the clinical
interpretation of the results will be retained, since data retention will
likely be associated with additional costs.
29
a Scoring scale:−100 (all strongly disagree challenge is important) to 100 (all strongly
agree).
Fig. 1. Project approach: ﬁrst module.
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included in Round 2 for re-assessment by the group. We also included
a new series of panel-suggested additional challenges for assessment
(suggested through open text boxes). The project team also revised
and re-presented four challenges from Round 1 that related to FDA
and CLIA (results from these questions were ambiguous, perhaps in
part because in the interim between rounds the FDA released a pro-
posed new framework for regulating in vitro diagnostics), and asked a
series of follow-up questions to conﬁrm and clarify the Round 1 results.
In both rounds, panelists assessed individual challenges using Likert
scales and performed ranking exercises to evaluate the relative impor-
tance of challenges (or categories of challenges) and the perceived fea-
sibility of addressing the challenges. Panelists had opportunities to
provide open-ended comments and suggestions throughout the ques-
tionnaire. Between Rounds 1 and 2, all participants were provided
with the results of the ﬁrst round: a 22-page packet displaying aggre-
gate scores (as calculated above) for each challenge (e.g., the data pre-
sented in Tables 1 and 2 below in graphical form) and an anonymized
summary of all the open-text comments organized by theme.
Questionnaires for Rounds 1 and 2 were administered online using
Qualtrics®. Individual survey links were sent to each participant to
allow the project team to track individual responses. Forty-three ex-
perts participated in the ﬁrst round and 35 participated in the second
round, although not all participants answered all questions. This type
of attrition is a well-known challenge of using the Delphi method
(Adler and Ziglio, 1996). However, for the purposes of the policy Delphi
survey, so long as attrition does not lead to homogenization of the group
composition (it did not in this case), we expect the essential underlying
logic of the method to remain intact.
Note also that Delphi surveys should not be construed as statistical
population sampling. The group participating in this survey was purpo-
sively sampled (Bryman, 2012) according to our criteria for expertise in
speciﬁed stakeholder categories. Our claim is not that this group is nec-
essarily representative of some population, but that the perspectives
and deliberations of this group are worth consideration due to the ex-
pertise and composition of the group.Respondents in Rounds 1 and 2were blind to each other's identities.
They were sent private, individualized email links to electronic surveys.
Email instructions were provided such that all participants were blind
copied. Only the project teamwas aware of the identities of the respon-
dents. The study was reviewed and approved by institutional review
boards (IRBs) at the Johns Hopkins University, Baylor University, and
the Chesapeake IRB.
The Delphi process underlying this report is summarized in Fig. 1.
3. Results
In Round 1, 19 challenges were assessed. Table 2 shows the weight-
ed score (described above) for each challenge assessed in Round 1. The
scores are all positive (not negative), indicating that as a group, overall,
the panelists ascribed some importance to each issue. However, lower
scores tend to indicate more disagreement and weaker support for the
importance of the challenge. Five challenges had a score of at least 60,
meaning there was overall agreement that these issues are important
barriers to clinical adoption of NGS. By this measure, the panel felt
that themost important policy challenge for NGSwas the ability of diag-
nostic companies to maintain proprietary databases. Notably, this chal-
lenge was also ranked as one of the least politically feasible to address.
The other high-scoring challenges in Round 1 were related to cover-
age and reimbursement of NGS testing: 1) the inability of coverage and
reimbursement frameworks to keep pace with innovation; 2) differing
payer standards for clinical utility leading to inconsistent policies for
coverage and reimbursement of NGS-based clinical testing; 3) payer re-
fusals to coverNGS testingwhen uncertainty existed around the speciﬁc
information needed for patient management; 4) and payer classiﬁca-
tion of NGS as investigational (by deﬁnition) and therefore not covered.
Challenges related to FDA and the Clinical Laboratories Improvement
Amendments (CLIA) were relatively low-scoring in Round 1.
The importance scores for the challenges assessed in Round 2 are
provided in Table 3. Again, the ability of diagnostic companies to main-
tain proprietary databases emerged as the most important barrier to
clinical adoption of NGS. In Round 2 follow-up and conﬁrmatory
Table 3
Round 2 individual challenge assessment scores for importance.
Challenge description Scorea
Diagnostic companies are able to maintain proprietary databases on the
substantial variety of clinically meaningful mutations found in patients.
Refusal to share this type of information could impede the development
of clinically useful NGS tests.
76
There is a lack of standardization for reanalysis and reporting updates to
variants calls.
63
There is a lack of standardization for reporting NGS test results (e.g.,
determining which results to report, how to effectively communicate
ﬁndings, and to whom those ﬁndings should be communicated).
60
Different payers have different evidentiary standards for assessing clinical
utility, leading to inconsistent policies on coverage and reimbursement
for NGS-based testing.
58
Some payers refuse to cover NGS because the speciﬁc patient
management decision to be informed by testing is unclear when
NGS-based testing is ordered.
56
Some payers refuse to cover NGS because the technology itself is
considered experimental, investigational, or unproven.
52
The clinical integration of NGS requires new infrastructure that includes,
for example, better EHR systems to store and cross-reference genomic
information with other health-related information to facilitate clinical
decision making.
50
CLIA cannot ensure accurate and valid NGS-based test results because the
Centers for Medicare and Medicaid Services (CMS) have not
promulgated speciﬁc standards for laboratories performing genetic
testing.
48
The inclusion of genetic counseling and communication of NGS test results
is not sufﬁciently standardized as part of clinical practice.
45
The lack of education and training of health care professional in the areas
of genetics and genomics is impeding the realization of clinical NGS.
45
The traditional framework many payers use for assessing diagnostic tests
for coverage cannot keep pace with the rate of NGS-based genomic
discovery.
38
The clinical integration of NGS raises questions about data ownership and
access, including the entitlements of patients and physicians.
37
FDA's authority to regulate tests and products depends on their intended
use. In the absence of speciﬁc clinical claims (predictive or diagnostic),
FDA may be limited in its ability to regulate NGS-based tests.
36
Under new HIPAA privacy rule amendments, patients may have
unrestricted access to protected health information (PHI), including raw
data (BAM, FASTQ, VCF) stored by laboratories covered by HIPAA.
21
FDA's newly proposed framework for regulating LDTs creates signiﬁcant
barriers to achieving the beneﬁts related to clinical integration of NGS.
20
There is no clear legal guidance on the scope of potential legal liability for
laboratories and clinicians in connection with the interpretation and
reporting of NGS results.
18
Patients and their caregivers are not sufﬁciently versed in genetics and
genomics to participate in decision making related to NGS testing.
17
Existing protections are not adequate to protect the privacy of patient data
in the context of clinical NGS.
−2
FDA's newly proposed framework for regulating LDTs fails to address
signiﬁcant risks related to clinical integration of NGS (e.g., incorrect
diagnosis, treatment, or prevention of disease).
−6
a Scoring scale:−100 (all strongly disagree challenge is important) to 100 (all strongly
agree).
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tain private variant databases as protected trade secrets while 66% op-
posed the patenting of complementary DNA strands or DNA primers.
In addition, 2 new challenges suggested by panelists in Round 1 had
scores of at least 60 in this assessment: the lack of standardization for
re-analysis and reporting updates to variant calls; and the lack of stan-
dardization for reporting NGS test results.
Although coverage and reimbursement issues dominated the chal-
lenges scoring highly important in Round 1, in Round 2 supplemental
questions, respondents were divided when asked if payers are “too re-
strictive” in covering NGS: 37% disagreed, 34% agreed, and 29%
expressed no opinion. When asked what types of testing payers should
cover:
• 77% of the panel favored coverage of NGS testing for tumor proﬁling.
• 70% of the panel favored coverage of whole genome and exomesequencing for rare diseases.
• 66% of the panel favored coverage for prenatal testing.
• 52% of the panel favored coverage for pharmacogenetic testing.
• 49% of the panel favored coverage for newborn screening.
• 29% favored coverage for disease risk prediction.
Most panelists believed payers should vary their standards of evi-
dence depending on clinical need and context (out of 32 panelists
responding, 63%were in favor, 16%were not in favor, and the remainder
took no position).
Individual FDA-related challenges did not score highly for impor-
tance in Round 1. When asked in Round 2 which elements of the NGS
clinical pipeline should be regulated, 54% favored FDA regulation of con-
sumables and arrays, 57% favored regulation of sequencing instrument
manufacturers, and 54% favored regulation of interpretation and
reporting of results. This latter result stands in contrast to a separate
set of questions in which only 40% agreed that interpretive services
should be subject to FDA regulation, while 63% indicated that interpre-
tive services constitute the practice of medicine. A minority endorsed
regulating other aspects of the NGS pipeline: 44% favored regulation of
performance of sequencing and 43% favored regulation of alignment
and annotation. Only 21% supported FDA regulation of data storage. A
majority (57%) indicated that mechanisms other than FDA oversight
could be used to address clinical risks to patients from the use of NGS.
Support for FDA's 2014 proposal to regulate laboratory-developed
tests (LDTs) was also mixed. Paradoxically, while the challenge “FDA's
newly proposed framework for regulating LDTs fails to address signiﬁ-
cant risks” made it into the top ﬁve results of the ﬁnal ranking exercise
(discussed below), it was the lowest-scoring item in individual chal-
lenge assessments (Table 3). The group was split on this question,
with somewhat more panelists disagreeing than agreeing that this is
an important barrier to clinical adoption of NGS.
The Delphi panel was generally optimistic about the future useful-
ness of clinical NGS, with 71% (24/34) agreeing or strongly agreeing
that “within the next ﬁve years, NGS will be a valuable tool across
many areas of clinical practice.”When asked in an open-ended question
to identify the areas of clinical practice in which NGS will be most valu-
able, the overwhelming answer was oncology (19 responses, as com-
pared to 4 or fewer for all other disease categories). In addition, 74% of
the panel viewed clinical risks to patients from the use of NGS-based
testing as moderate to low.
As a ﬁnal step in Round 2, panelists were asked to select what they
considered to be the 3 most important issues from an overall list of
the 19 challenges presented. For the 35 participating panelists, the 5
challenges most often picked for the top 3 were:
1) Tied for ﬁrst place: “Diagnostics companies are able to maintain
proprietary databases on the substantial variety of clinically
meaningful mutations found in patients. Refusal to share this type
of information could impede the development of clinically useful
NGS tests”.
2) Tied for ﬁrst place: “Different payers have different evidentiary stan-
dards for assessing clinical utility, leading to inconsistent policies on
coverage and reimbursement for NGS-based testing”.
3) Second place: “There is a lack of standardization for reporting NGS
test results (e.g., determining which results to report, how to effec-
tively communicate ﬁndings, and to whom those ﬁndings should
be communicated)” (panelist-suggested challenge).
4) Tied for third place: “Some payers refuse to cover NGS because the
speciﬁc patient management decision to be informed by testing is
unclear when NGS-based testing is ordered”.
5) Tied for third place: “FDA's newly proposed framework for regulat-
ing LDTs fails to address signiﬁcant risks related to clinical integra-
tion of NGS (e.g., incorrect diagnosis, treatment, or prevention of
disease)”.
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The exercise described in this article has potential limitations in that,
as noted above, the panel cannot necessarily be seen as representative
of a larger population of experts. Moreover, a somewhat different com-
position of expert stakeholders participated in each round, and both of
these groups differed in composition somewhat from that of the larger
group of experts who originally agreed to participate. The effect that
these variations may have had on the exercise cannot be predicted,
since the opinions of the “missing” stakeholders are unknown. Never-
theless, the policy Delphi is not designed for precise reproducibility,
but as a structured exercise to bring out the values and opinions of ex-
pert stakeholders whose thoughts are deemed relevant to the underly-
ing questions. Our key concern therefore was to preserve a
heterogeneous group composed of key stakeholder categories.
The results of this exercise consistently spoke to a majority of the
Delphi panel's discomfort with proprietary mutation databases as a sig-
niﬁcant barrier to effective clinical adoption of NGS. Promoting and en-
couraging data-sharing is one clear antidote to assuring that important
mutation data is available to clinicians and patients when needed. Nu-
merous repositories are in various stages of development with content
that may be overlapping, complementary or redundant (Rubenstein et
al., 2015). The existence of so many repositories and efforts to curate
data about genomic variation could splinter or Balkanize data when
data-pooling can be more effective for assessing the meaning of geno-
mic variation in populations. The curation projects and databases are
developing protocols to enable pooling of data, e.g., through the
Global Alliance for Genomics andHealth andmany other collaborations.
Establishing andmaintaining the data repositories, norms and practices
for sharing data and samples, and interfaces for clinical use will be chal-
lenges through the foreseeable future (Ray). For this reason, FDA's pro-
posal to use a public repository like ClinVar as a “regulatory grade”
database that can form the basis for in vitro diagnostic device clearances
is a potentially positive development, since it would promote contribu-
tions to a speciﬁc public resource and increase the likelihood that this
resource would continue to receive funding (US Food and Drug
Administration, 2015). This prospect is made more promising by the
Precision Medicine Initiative's provision to provide $10 M in funding
to the FDA (FACT SHEET). Vice President Biden's recently announced
“cancer moonshot” may also direct resources to encourage data-shar-
ing, but some observers worry it will disrupt existing initiatives
(Hayden, 2016). In any event, companies desirous of maintaining pro-
prietary databases are unlikely to participate in public-private partner-
ships for data-sharing without compelling incentives (Cook-Deegan et
al., 2013).
The results additionally point overall to a perception that payers are
a bottleneck to patient access to promising genomic testing. The cover-
age challenge ranked as most important reveals a perceived inconsis-
tency in the standards payers use to assess clinical utility of NGS,
leading to inconsistent coverage policies. Yet a 2012 review of 10
major commercial health plan policies found approximately 90% consis-
tency in coverage decisions for genetic and pharmacogenetic tests, even
though the decisions were sometimes based on somewhat different
bodies of evidence (Hresko andHaga, 2012). If payers have substantive-
ly different evidence standards for utility, it does not seem to translate
into signiﬁcantly different coverage decisions for genetic and pharma-
cogenetic testing. With respect to NGS testing speciﬁcally, our panel
may see growing variability in the way different payers approach test-
ing, not because of differing standards for utility, but because of payer
uncertainty over the technology, the proliferation of new clinical uses,
and challenges in managing the information NGS produces.
However, the overall perception of payers as a bottleneck has some
empirical support. Relatively few genetic and pharmacogenomic tests
on the market have even undergone evidence reviews for coverage be-
cause of an overall lack of clinical utility studies available to review
(Hresko and Haga, 2012). Thus, a bottleneck exists that is related tothe way payers deﬁne utility (generally in terms of improved health
outcomes for patients when test information is used) and the lack of
supporting evidence for this kind of clinical utility, rather than be-
tween-payer inconsistency in the deﬁnition or standards. Groups such
as the American College of Medical Genetics (ACMG) have taken posi-
tions on how clinical utility should be deﬁned (Anon., 2015). These
statements reﬂect a tension between stakeholders who would broaden
the concept of utility to include patient beneﬁts not directly measured
as health outcomes, and more restrictive deﬁnitions that payers tend
to favor, such as that of the Evaluation of Genomic Applications in Prac-
tice and Prevention (EGAPP)Working Group (Teutsch et al., 2009). This
disconnect is likely to be exacerbated by NGS, given an expanding uni-
verse of potential clinical applications with expanding capabilities for
genomic analysis.
Despite health plans' ability to help or hinder patient access through
coverage policy, the importance of payers as stakeholders to be engaged
in policy is not fully appreciated. The President's PrecisionMedicine Ini-
tiative puts an emphasis on cancer as an initial priority, devoting $70M
of the proposed annual increment of NIH's budget to work at the Na-
tional Cancer Institute (FACT SHEET). Yet, the Presidential Initiative's
call for public-private partnerships to build an enhanced cancer re-
search enterprise seeks to engage “academic medical centers, re-
searchers, foundations, privacy experts, medical ethicists, and medical
product innovators”—not payers. Presumably payers were excluded be-
cause they are not traditionally conceived as research organizations. Yet
some major health plans are making major investments in data infra-
structure and data mining, such as the UnitedHealth-owned Optum
Labs' partnership with theMayo Clinic (Wallace et al., 2014). Moreover,
excluding payers could fail to address one of the foremost chokepoints
in translating NGS technology into clinical use. Without health plan as-
sent to the products of research (i.e., agreement that clinical utility of
new genomic tests has been established via research ﬁndings), patient
access to new valuable discoveries may be hindered.
The Delphi panel also identiﬁed oncology as a key area of growth for
the clinical use of NGS—and by extension a clinical domain inwhich the
policy challenges of clinically integrating NGS data into clinical practice
will ﬁrst be confronted. Payer engagement is therefore essential for con-
structive policy solutions in this arena. Several current initiatives do
reach out to payers as partners in discussing coverage of clinical NGS
for oncology. These include the Targeted Agent and Molecular
Proﬁling Registry (TAPUR), the Molecular Evidence Development
Consortium (MED-C), (both of which ask payers to cover testing as
part of genomic evidence generation in oncology), the Tapestry
Network's SPOT/Dx working group (not speciﬁcally focused on payer
coverage of clinical NGS, but payers are involved in discussions of real
world evidence for genomics) (SPOT/DxWorking Group), and the Cen-
ter for Medical Technology Policy's Green Park Collaborative initiative
on NGS coverage standards and policy (CMTP-Funded Effort to
Develop Evidence Standards for NGS Cancer Testing; Center for
Medical Technology Policy, 2015).
While the panel expressed misgivings about the role of health plans
as a hindrance to patient access, many panelists approved maintaining
relatively high standards of clinical utility, prioritizing coverage of geno-
mics for care of serious disease. Overall, the group seemed to desire a
middle groundwhere reasonable standards of utility are applied consis-
tently, but not in a way that hinders clinician discretion to gather geno-
mic information in complex clinical scenarios, especially in important
clinical areas like oncology.
For the project team, the most surprising ﬁnding from this exercise
thus far has been the lack of relative importance assigned to individual
challenges addressing FDA regulation as a potential barrier to clinical
NGS testing. The new FDA proposed framework for regulating LDTs
had just been released when the Round 1 survey was underway. The
team therefore used Round 2 to probe the new developments. We
found that our participants were eager to provide us with open-ended
comments expressing opinions on the ongoing controversy over FDA's
24 D.A. Messner et al. / Applied & Translational Genomics 10 (2016) 19–24authority to regulate LDTs (Evans andWatson, 2015; Evans et al., 2015;
Lander, 2015; Litwack et al., 2015; Sharfstein, 2015). Nevertheless, FDA
regulation of NGS continued to poll as less important than other chal-
lenges for clinical NGS. Even though an FDA policy challenge tied for
third place in the overall ranking at the conclusion of Round 2, as
noted, this speciﬁc policy challenge had the weakest response when
evaluated on an individual basis (with a weighted score of −6; only
37% of respondents said it was an important challenge). This attitude
might be attributed either as skepticism that FDA reforms will ever be
implemented, or as acceptance of the FDA's presence in this arena as rel-
atively unobtrusive compared to other challenges.
“Lack of standardization for reporting NGS test results”was the only
participant-suggested challenge that ranked highly important by partic-
ipants in Round 2. However, the speciﬁc nature of the challengewas un-
clear to panelists; i.e., is the challenge “determining which results to
report,” or “how to effectively communicate ﬁndings,” or “to whom
should ﬁndings be communicated?” These questions are being further
evaluated in the last two Delphi rounds.
Advanced sequencing technologies are capable of rapidly generating
enormous amounts of genomic information with increasing cost effec-
tiveness. These advances hold great promise for bringing genomics
into the clinic for use in precision medicine. However, they also strain
the traditional policy structures for regulation, coverage and reimburse-
ment, and intellectual property. We identiﬁed key areas of concern in a
mapping exercise with an expert Delphi panel to identify the most im-
portant policy challenges to clinical adoption of NGS. The panel's future
assessment of potential solutions to key challenges and the pros and
cons associated with possible policy remedies will be explored in fur-
ther investigation.
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